Seek Returns logo

ALGN vs. INSP: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ALGN and INSP, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

ALGN’s market capitalization of 14.27 billion USD is substantially larger than INSP’s 3.79 billion USD, indicating a significant difference in their market valuations.

With betas of 1.64 for ALGN and 1.29 for INSP, both stocks show similar sensitivity to overall market movements.

SymbolALGNINSP
Company NameAlign Technology, Inc.Inspire Medical Systems, Inc.
CountryUSUS
SectorHealthcareHealthcare
IndustryMedical - DevicesMedical - Devices
CEOJoseph M. HoganTimothy P. Herbert
Price196.82 USD128.48 USD
Market Cap14.27 billion USD3.79 billion USD
Beta1.641.29
ExchangeNASDAQNYSE
IPO DateJanuary 30, 2001May 3, 2018
ADRNoNo

Historical Performance

This chart compares the performance of ALGN and INSP by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ALGN vs. INSP: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ALGN

10.67%

Medical - Devices Industry

Max
49.04%
Q3
9.53%
Median
-7.46%
Q1
-32.83%
Min
-82.64%

In the upper quartile for the Medical - Devices industry, ALGN’s Return on Equity of 10.67% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

INSP

10.00%

Medical - Devices Industry

Max
49.04%
Q3
9.53%
Median
-7.46%
Q1
-32.83%
Min
-82.64%

In the upper quartile for the Medical - Devices industry, INSP’s Return on Equity of 10.00% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

ALGN vs. INSP: A comparison of their ROE against the Medical - Devices industry benchmark.

Return on Invested Capital

ALGN

9.78%

Medical - Devices Industry

Max
21.88%
Q3
6.63%
Median
-1.11%
Q1
-21.08%
Min
-51.95%

In the upper quartile for the Medical - Devices industry, ALGN’s Return on Invested Capital of 9.78% signifies a highly effective use of its capital to generate profits when compared to its peers.

INSP

6.90%

Medical - Devices Industry

Max
21.88%
Q3
6.63%
Median
-1.11%
Q1
-21.08%
Min
-51.95%

In the upper quartile for the Medical - Devices industry, INSP’s Return on Invested Capital of 6.90% signifies a highly effective use of its capital to generate profits when compared to its peers.

ALGN vs. INSP: A comparison of their ROIC against the Medical - Devices industry benchmark.

Net Profit Margin

ALGN

10.29%

Medical - Devices Industry

Max
44.80%
Q3
9.77%
Median
-5.53%
Q1
-29.37%
Min
-87.68%

A Net Profit Margin of 10.29% places ALGN in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.

INSP

7.92%

Medical - Devices Industry

Max
44.80%
Q3
9.77%
Median
-5.53%
Q1
-29.37%
Min
-87.68%

INSP’s Net Profit Margin of 7.92% is aligned with the median group of its peers in the Medical - Devices industry. This indicates its ability to convert revenue into profit is typical for the sector.

ALGN vs. INSP: A comparison of their Net Profit Margin against the Medical - Devices industry benchmark.

Operating Profit Margin

ALGN

14.69%

Medical - Devices Industry

Max
30.13%
Q3
13.12%
Median
3.47%
Q1
-24.42%
Min
-80.56%

An Operating Profit Margin of 14.69% places ALGN in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

INSP

5.93%

Medical - Devices Industry

Max
30.13%
Q3
13.12%
Median
3.47%
Q1
-24.42%
Min
-80.56%

INSP’s Operating Profit Margin of 5.93% is around the midpoint for the Medical - Devices industry, indicating that its efficiency in managing core business operations is typical for the sector.

ALGN vs. INSP: A comparison of their Operating Margin against the Medical - Devices industry benchmark.

Profitability at a Glance

SymbolALGNINSP
Return on Equity (TTM)10.67%10.00%
Return on Assets (TTM)6.71%9.10%
Return on Invested Capital (TTM)9.78%6.90%
Net Profit Margin (TTM)10.29%7.92%
Operating Profit Margin (TTM)14.69%5.93%
Gross Profit Margin (TTM)69.87%84.65%

Financial Strength

Current Ratio

ALGN

1.21

Medical - Devices Industry

Max
12.68
Q3
6.30
Median
4.05
Q1
1.85
Min
0.01

ALGN’s Current Ratio of 1.21 falls into the lower quartile for the Medical - Devices industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

INSP

9.01

Medical - Devices Industry

Max
12.68
Q3
6.30
Median
4.05
Q1
1.85
Min
0.01

INSP’s Current Ratio of 9.01 is in the upper quartile for the Medical - Devices industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

ALGN vs. INSP: A comparison of their Current Ratio against the Medical - Devices industry benchmark.

Debt-to-Equity Ratio

ALGN

0.03

Medical - Devices Industry

Max
2.34
Q3
1.09
Median
0.37
Q1
0.08
Min
0.00

Falling into the lower quartile for the Medical - Devices industry, ALGN’s Debt-to-Equity Ratio of 0.03 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

INSP

0.05

Medical - Devices Industry

Max
2.34
Q3
1.09
Median
0.37
Q1
0.08
Min
0.00

Falling into the lower quartile for the Medical - Devices industry, INSP’s Debt-to-Equity Ratio of 0.05 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

ALGN vs. INSP: A comparison of their D/E Ratio against the Medical - Devices industry benchmark.

Interest Coverage Ratio

ALGN

--

Medical - Devices Industry

Max
18.18
Q3
7.53
Median
0.85
Q1
-9.80
Min
-33.94

Interest Coverage Ratio data for ALGN is currently unavailable.

INSP

2,264.36

Medical - Devices Industry

Max
18.18
Q3
7.53
Median
0.85
Q1
-9.80
Min
-33.94

With an Interest Coverage Ratio of 2,264.36, INSP demonstrates a superior capacity to service its debt, placing it well above the typical range for the Medical - Devices industry. This stems from either robust earnings or a conservative debt load.

ALGN vs. INSP: A comparison of their Interest Coverage against the Medical - Devices industry benchmark.

Financial Strength at a Glance

SymbolALGNINSP
Current Ratio (TTM)1.219.01
Quick Ratio (TTM)1.087.44
Debt-to-Equity Ratio (TTM)0.030.05
Debt-to-Asset Ratio (TTM)0.020.04
Net Debt-to-EBITDA Ratio (TTM)-0.94-0.29
Interest Coverage Ratio (TTM)--2264.36

Growth

The following charts compare key year-over-year (YoY) growth metrics for ALGN and INSP. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ALGN vs. INSP: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ALGN vs. INSP: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ALGN vs. INSP: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ALGN

0.00%

Medical - Devices Industry

Max
3.57%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ALGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

INSP

0.00%

Medical - Devices Industry

Max
3.57%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSP currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ALGN vs. INSP: A comparison of their Dividend Yield against the Medical - Devices industry benchmark.

Dividend Payout Ratio

ALGN

0.00%

Medical - Devices Industry

Max
102.12%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ALGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

INSP

8.84%

Medical - Devices Industry

Max
102.12%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSP’s Dividend Payout Ratio of 8.84% is in the upper quartile for the Medical - Devices industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

ALGN vs. INSP: A comparison of their Payout Ratio against the Medical - Devices industry benchmark.

Dividend at a Glance

SymbolALGNINSP
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%8.84%

Valuation

Price-to-Earnings Ratio

ALGN

35.35

Medical - Devices Industry

Max
90.56
Q3
56.92
Median
43.19
Q1
21.79
Min
5.55

ALGN’s P/E Ratio of 35.35 is within the middle range for the Medical - Devices industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

INSP

57.38

Medical - Devices Industry

Max
90.56
Q3
56.92
Median
43.19
Q1
21.79
Min
5.55

A P/E Ratio of 57.38 places INSP in the upper quartile for the Medical - Devices industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

ALGN vs. INSP: A comparison of their P/E Ratio against the Medical - Devices industry benchmark.

Forward P/E to Growth Ratio

ALGN

3.34

Medical - Devices Industry

Max
6.56
Q3
3.52
Median
2.22
Q1
0.55
Min
0.03

ALGN’s Forward PEG Ratio of 3.34 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.

INSP

1.74

Medical - Devices Industry

Max
6.56
Q3
3.52
Median
2.22
Q1
0.55
Min
0.03

INSP’s Forward PEG Ratio of 1.74 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.

ALGN vs. INSP: A comparison of their Forward PEG Ratio against the Medical - Devices industry benchmark.

Price-to-Sales Ratio

ALGN

3.58

Medical - Devices Industry

Max
15.74
Q3
8.12
Median
3.40
Q1
2.37
Min
0.42

ALGN’s P/S Ratio of 3.58 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

INSP

4.51

Medical - Devices Industry

Max
15.74
Q3
8.12
Median
3.40
Q1
2.37
Min
0.42

INSP’s P/S Ratio of 4.51 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ALGN vs. INSP: A comparison of their P/S Ratio against the Medical - Devices industry benchmark.

Price-to-Book Ratio

ALGN

3.82

Medical - Devices Industry

Max
16.65
Q3
8.03
Median
3.73
Q1
1.92
Min
0.65

ALGN’s P/B Ratio of 3.82 is within the conventional range for the Medical - Devices industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

INSP

6.00

Medical - Devices Industry

Max
16.65
Q3
8.03
Median
3.73
Q1
1.92
Min
0.65

INSP’s P/B Ratio of 6.00 is within the conventional range for the Medical - Devices industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

ALGN vs. INSP: A comparison of their P/B Ratio against the Medical - Devices industry benchmark.

Valuation at a Glance

SymbolALGNINSP
Price-to-Earnings Ratio (P/E, TTM)35.3557.38
Forward PEG Ratio (TTM)3.341.74
Price-to-Sales Ratio (P/S, TTM)3.584.51
Price-to-Book Ratio (P/B, TTM)3.826.00
Price-to-Free Cash Flow Ratio (P/FCF, TTM)22.6248.06
EV-to-EBITDA (TTM)16.8048.34
EV-to-Sales (TTM)3.394.48